Add FDA press release about J&J emergency use authorization

README.md

@@ -318,7 +318,7 @@ Note that the WHO will generally be unable to make statements that their more pr
 * [Pfizer-BioNTech COVID-19 vaccine and related biological product advisory committee briefing document](https://www.fda.gov/media/144246/download) announces that this vaccine meets the FDA success criteria, with vaccine efficacy after the booster dose at 95.0%, counting 8 COVID-19 cases in the vaccine group compared to 162 COVID-19 cases in the placebo group, with a 95% credible interval of 90.3% to 97.6%
 * [Pfizer and BioNTech Announce Vaccine Candidate Against COVID-19 Achieved Success in First Interim Analysis from Phase 3 Study](https://www.pfizer.com/news/press-release/press-release-detail/pfizer-and-biontech-announce-vaccine-candidate-against) in a press release where they state that their BNT162b2 vaccine has more than 90% efficacy, based on 94 participant who got COVID-19 during the trial, without any serious safety concerns; the article [Vaccine Efficacy Data!](https://blogs.sciencemag.org/pipeline/archives/2020/11/09/vaccine-efficacy-data) by Derek Lowe provides an early opinion on these results
 * [Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine](https://www.nejm.org/doi/pdf/10.1056/NEJMoa2034577) is the phase III study paper
-* [Janssen Ad26.COV2.S Vaccine for the Prevention of COVID-19 briefing document](https://www.fda.gov/media/146217/download) was released by the FDA endorses the Johnson&Johnson vaccine; [Dered Lowe](https://blogs.sciencemag.org/pipeline/archives/2021/02/24/the-jj-vaccine-at-the-fda) and [StatNews](https://www.statnews.com/2021/02/24/new-data-shed-light-on-efficacy-of-jjs-single-dose-vaccine-against-covid-19/) discuss the data
+* [FDA Issues Emergency Use Authorization for Third COVID-19 Vaccine](https://www.fda.gov/news-events/press-announcements/fda-issues-emergency-use-authorization-third-covid-19-vaccine) after the document [Janssen Ad26.COV2.S Vaccine for the Prevention of COVID-19 briefing document](https://www.fda.gov/media/146217/download) was released by the FDA endorsing the Johnson&Johnson vaccine; [Dered Lowe](https://blogs.sciencemag.org/pipeline/archives/2021/02/24/the-jj-vaccine-at-the-fda) and [StatNews](https://www.statnews.com/2021/02/24/new-data-shed-light-on-efficacy-of-jjs-single-dose-vaccine-against-covid-19/) discuss the data
 * [Pfizer and BioNTech Initiate a Study as Part of Broad Development Plan to Evaluate COVID-19 Booster and New Vaccine Variants](https://investors.biontech.de/news-releases/news-release-details/pfizer-and-biontech-initiate-study-part-broad-development-plan) as announced in a BioNTech press release, where the company reveals it plans to study the effects of a third booster shots of 30µg of the original vaccine, as well as ongoing discussions with regulatory agencies about potential approval of vaccines specific to B.1.351 (South African) or other variants
 * [Estimating the effectiveness of the Pfizer COVID-19 BNT162b2 vaccine after a single dose. A reanalysis of a study of ‘real-world’ vaccination outcomes from Israel](https://www.medrxiv.org/content/10.1101/2021.02.01.21250957v1.full)
 * [Pfizer’s vaccine appears to reduce coronavirus transmission](https://www.sciencenews.org/article/coronavirus-covid-19-pfizer-vaccine-may-reduce-transmission) as evidenced by a couple of studies estimating lower viral load in vaccinated people